Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLANET trial of intravitreal aflibercept with or without rescue photodynamic therapy for polypoidal choroidal vasculopathy
2013-004464-54Phase 4Completed
- Sponsor
- Bayer
- Start
- Feb 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aflibercept and verteporfin in polypoidal choroidal vasculopathy (PCV) and exudative macular degeneration (2 arms), sponsored by Bayer. Primary endpoint: Mean change in best corrected visual acuity from baseline to Week 52. Started Feb 2014; status: completed.
02
Drugs
afliberceptverteporfin
03
Conditions
polypoidal choroidal vasculopathy (PCV)exudative macular degeneration
Beyond the preview
Go deeper on 2013-004464-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004464-54.